ABSTRACT NR1/NR2A is a subtype of N-methyl-D-aspartate receptors (NMDARs), which are glutamate and glycine-gated Ca 2ϩ -permeable channels highly expressed in the central nervous system. A high-throughput screening (HTS) campaign using human osteosarcoma (U-2 OS) cells transiently transduced with NR1/NR2A NMDAR subunits, tested in a specifically designed fluorometric imaging plate reader (FLIPR)/Ca 2ϩ assay, identified sulfonamide derivative series, exemplified by
Introduction
N-methyl-D-aspartate receptors (NMDARs) are ligandgated cation-selective channels that are highly expressed in the central nervous system (Köhr, 2006) . NMDAR activity is crucial to brain functions such as circuit development (McKinney, 2010 ) and learning and memory (Li and Tsien, 2009) , and dysfunction of NMDAR activity has been implicated in a variety of neuropathological conditions, including stroke, epilepsy, schizophrenia, depression, Huntington's disease, Alzheimer's disease, Parkinson's disease, and multiple sclerosis (Lipton, 2006; Large, 2007; Milnerwood et al., 2010) . NMDARs are unusual ligand-gated ion channels because their activation requires the relief of Mg 2ϩ block by membrane depolarization (Mayer et al., 1984) and the concomitant binding of two agonists: glycine (or D-serine) and Lglutamate (Johnson and Ascher, 1987; Mothet et al., 2000) . The opening of NMDARs leads to an influx of cations, including Ca 2ϩ , which initiates the signal transduction cascade. The majority of NMDARs are tetrameric complexes (Mayer, 2006) , consisting of two glycine-binding NR1 subunits and two glutamate-binding NR2 subunits (Collingridge et al., 2009) . NR1 is coded by a single gene with at least eight different splice variants; four different NR2 genes originate NR2A, NR2B, NR2C, and NR2D subunits (Paoletti and Neyton, 2007) . NMDARs containing different NR2 subunits have different pharmacological and kinetic properties (Vicini et al., 1998; Yuan et al., 2009) .
NR2 subunits show distinct anatomical localization, providing an opportunity to target specific neuronal circuits using subunit-selective modulators. Ifenprodil has been the prototype of selective NR1/NR2B receptor antagonists (Williams, 1993) , which are able to bind to the NR2B N-terminal domain (NTD) and have been used to evaluate the role of this subunit in brain function and diseases. Antagonists binding at the NR2B NTD might have therapeutic potential in pain, mood disorders, and neurodegenerative diseases (Mony et al., 2009 ). An involvement of NR1/NR2A receptor has been suggested in pathological conditions such as anxiety and depression (Boyce- Rustay and Holmes, 2006) . Despite the importance of NMDA receptors in many neurological disorders, antagonists that are more than 10-fold selective for NR2A, NR2C, or NR2D have not yet been identified, hampering a deeper understanding of their physiological role in brain functions. To address the need for new pharmacological tools, a program was established that included a highthroughput screening (HTS) campaign on approximately 2 million compounds and was aimed at identifying NR2A selective compounds.
Materials and Methods
Compound Sources. The compounds used in this study were as follows: compounds 1 to 5, 7, 8, 10, and 13 were purchased from Enamine (Kiev, Ukraine); compounds 6, 9, and 11 were purchased from ChemDiv (San Diego, CA); and compound 12 was purchased from Asinex (Moscow, Russia). [(R)-{[(1S)-1-(4-bromophenyl)ethyl-]amino}(2,3-dioxo-1,2,3,4-tetrahydro-5-quinoxalinyl)methyl]phosphonic acid (NVP-AAM077) was obtained as the corresponding diammonium salt by high-performance liquid chromatography separation of diasteroisomeric mixture [{[(1S)-1-(4-bromophenyl)ethyl]amino}(2,3-dioxo-1,2, 3,4-tetrahydro-5-quinoxalinyl)methyl]phosphonic acid tetrasodium hydrate (Sigma-Aldrich, Milan, Italy). Memantine hydrochloride, (ϩ)-MK-801 hydrogen maleate, 1-(1-phenylcyclohexyl)piperidine (phencyclidine) hydrochloride, and 4-{(1R,2S)-1-hydroxy-2-methyl-3-[4-(phenylmethyl)-1-piperidinyl]propyl}phenol (Ro 25-6981) maleate were purchased from Sigma-Aldrich. All other chemicals were of analytical grade and obtained from commercial sources.
Computational Work. HTS concentration response curve (CRC) hits were prioritized according to their ligand efficiency (LE) and ligand lipophilicity efficiency (LLE) indexes as well as their selectivity compared with NR1/NR2B receptor. The LE formula was derived from Hopkins et al. (2004) to normalize the potency of a compound with respect to its size: LE ϭ pIC 50 /number of nonhydrogen atoms.
Calculated partition coefficient (cLogP), obtained with the use of Daylight 4.81 software (Daylight Chemical Information Systems, Laguna Niguel, CA) was used to calculate LLE to maximize the minimally acceptable lipophilicity per unit of in vitro potency, according to Leeson and Springthorpe (2007) : LLE ϭ pIC 50 Ϫ cLogP. Hit expansion was performed by fishing out derivatives from inhouse repositories with the use of two-dimensional similarity searches carried out with an in-house developed tool, followed by visual compound inspection.
cDNAs Coding for NMDAR Subunits. cDNAs coding for human NMDAR subunits were transiently transduced in human osteosarcoma (U-2 OS) cells (LGC Standards/American Type Culture Collection, Teddington, UK) through BacMam vectors (Condreay et al., 1999) for fluorometric imaging plate reader (FLIPR; Molecular Devices, Sunnyvale, CA) assays or transfected in human embryonic kidney (HEK) 293T cells (LGC Standards/American Type Culture Collection) through plasmid vectors for patchclamp experiments: pcDNA3.1topo plasmids were used for NR1, NR2A, and NR2B subunits, whereas pCMV6-XL5 plasmids (Origene, Rockville, MD) were used for the NR2D subunit. pEGFP-N1 plasmid (Clontech, Mountain View, CA), encoding a red-shifted variant of wild-type GFP optimized for brighter fluorescence and higher expression in mammalian cells, was used to select transfected cells for patch clamp experiments.
FLIPR/Ca 2؉ Assay in U-2 OS Cells Expressing NMDAR. FLIPR/Ca 2ϩ experiments on recombinant receptors were conducted using U-2 OS cells, because they are efficiently transduced through BacMam vector (Condreay et al., 1999) and they adhere strongly to 384-well plates. Cryopreserved U-2 OS aliquots were thawed and suspended in Dulbecco's modified Eagle's medium/Ham's F-12 medium (Invitrogen, Milan, Italy), and supplemented with 10% (v/v) dialyzed fetal calf serum (Invitrogen) and 0.3 mM MgCl 2 . Suspended cells were added with 500 M ketamine (Merial Italia, Milan, Italy), 3% (v/v) NR1 BacMam, 6% (v/v) NR2A (or NR2B) BacMam, and seeded in black-walled clear-based 384-well plates (Greiner Bio-One GmbH, Frickenhausen, Germany) at a density of 18,000 cells/well in culture medium and maintained overnight (5% CO 2 at 37°C).
Cells grown overnight were directly added with the cytoplasmic calcium indicator, Fluo-4 (Invitrogen) in the acetoxylmethyl (AM) ester form (2 M) in assay buffer at 37°C for 1 h. Assay buffer contained 145 mM NaCl, 5 mM KCl, 1 mM CaCl 2 , 1 g/liter D-(ϩ)-glucose, 20 mM HEPES (pH adjusted to 7.3 with NaOH), and 2.5 mM probenecid (Sigma-Aldrich). Probenecid, an inhibitor of organic anion transport, was added to prevent intracellular Fluo-4 efflux.
After Fluo-4 AM loading, cell plates were washed two or three times, for NR1/NR2A or NR1/NR2B receptor, respectively, with the assay buffer using the EMBLA 384 instrument (Molecular Devices, Sunnyvale, CA) to remove ketamine; 30 l of assay buffer was left in each well at the end of the washing.
Cell plates were then placed into a FLIPR to monitor cell fluorescence (excitation wavelength at 488 nm, emission wavelength at 540 nm) 30 s before and until 5 min after 10 l/well drug addition (Sullivan et al., 1999) . Antagonist addition was able to induce a measurable decrease in fluorescence (see Supplemental Data), similarly to what was reported for other NMDARs (Hansen et al., 2010) .
Compounds dissolved in DMSO were 50-fold diluted with assay buffer plus 0.01% Pluronic F-127 (Sigma-Aldrich) before the FLIPR/ Ca 2ϩ experiment. For concentration response curve experiments, serial dilution (1:3, 11 points) of compounds in DMSO was performed using a Biomek FX (Beckman Coulter, Fullerton, CA). Stock solutions of 100 mM L-glutamate and 400 mM glycine were prepared in water and stored at Ϫ20°C, then diluted at the desired concentration jpet.aspetjournals.org in assay buffer on the experimental day. In mode-of-action studies, a second addition of 1 mM glycine or L-glutamate was done by FLIPR instrument, 5 min after compound addition, and fluorescence was measured for an additional 5 min.
FLIPR/Ca 2؉ Assay in Rat Brain Cortical Cells. Cortical neuronal cultures were obtained from embryonic day 18/19 SpragueDawley rats (Charles River Italica, Calco, Italy). Animal manipulations were performed according to Italian law (art. 7, Legislative Decree No.116, 27 January 1992) , which acknowledged the European Directive 86/609/EEC and GlaxoSmithKline policy on the care and use of laboratory animals and related codes of practice. Rat brains were dissected out and cortices were quickly isolated at 4°C in Hanks' balanced salt solution supplemented with HEPES (HBSSH buffer), containing 5 mM KCl, 0.4 mM KH 2 PO 4 , 138 mM NaCl, 0.3 mM Na 2 HPO 4 , 5.5 mM D-glucose, 26 mM phenol red, 100 U/ml penicillin, 100 g/ml streptomycin, and 10 mM HEPES at pH 7.3. Cortical cells were treated with HBSSH buffer added with 0.1% trypsin at 37°C for 10 min. In the last 5 min of incubation, 166 g/ml DNase I (Sigma-Aldrich) was added. After a single wash with HBSSH buffer containing 10% fetal bovine serum (Invitrogen) and two additional washes with HBSSH buffer, cells were mechanically dissociated by triturating with Pasteur pipettes and placed in poly-L-lysine-coated 384-well plates (Greiner Bio-One GmbH) at a density of 8000 cells/well in serum-free Neurobasal medium (Invitrogen) added with B27 supplement (Invitrogen), 500 M glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin. Cells were grown at 37°C, 5% CO 2 . Addition of fresh medium was made at 3 and 10 days, and the cells were used for intracellular Ca 2ϩ measurements at 15 days after plating. Intracellular Ca 2ϩ measurements were made using a FLIPR TETRA (Molecular Devices). On the assay day, cultures were washed two times with physiological salt solution buffer (145 mM NaCl, 1 g/liter glucose, 5 mM KCl, 2 mM CaCl 2 , and 20 mM HEPES) supplemented with 2.5 mM probenecid. Then, loading solution (physiological salt solution supplemented with 2.5 mM probenecid, 0.04% Pluronic F-127, and 2 M Fluo-4 AM) was added. After 40 min at 37°C, cells were washed three times as described above and transferred to the FLIPR TETRA . Ca 2ϩ responses were measured with excitation wavelength at 470 to 495 nm and emission wavelength at 515 to 575 nm. Camera gain and intensity were adjusted for each plate to yield a minimum baseline fluorescence of 300 relative light units. To assess the effect of NMDAR antagonists on the NMDA-triggered Ca 2ϩ response, cells were exposed first to different concentrations of test drugs (master plate at 4ϫ concentration) for 10 min, then to a submaximal concentration of NMDA (EC 80 , 10 -20 M) (master plate at 5ϫ concentration) for 3 min. Five fluorescence readings were taken to measure baseline, before compound addition.
FLIPR/Ca 2؉ Data Analysis. FLIPR/Ca 2ϩ functional responses were measured in U-2 OS experiments as fluorescence intensity at 5 min after drug addition, normalized to the maximal response evoked by 30 M (ϩ)-MK-801 NMDAR blocker on the same plate. Iterative curve fitting and parameter estimations were carried out using a four-parameter logistic model in an Activity Base (IDBS, Guilford, UK) environment.
In rat cortical neurons, Ca 2ϩ responses were quantified as areaunder-the-curve analysis of the time-response data over baseline and normalized to the response evoked by EC 80 of NMDA. To determine antagonist potencies, concentration-response curves were generated for each compound by fitting to a four-parameter logistic equation (GraphPad Software Inc., San Diego, CA). The percentage block of the Ca 2ϩ response and the calculated pIC 50 values are expressed as mean Ϯ S.E.M. of at least three independent experiments, each performed at least in triplicate.
Whole-Cell Patch-Clamp Electrophysiology in HEK 293T Cells Expressing NMDAR. Whole-cell patch-clamp recording was performed on HEK 293T cells, and cells were transiently transfected with human NMDAR subunits and EGFP plasmid (see cDNA Coding for NMDAR Subunits). Electrophysiology experiments were carried out using an EPC-9 amplifier (HEKA, Lambrecht/Pfalz, Germany). Each cell was held at Ϫ60 mV throughout the recording, performed at a sampling rate of 1 kHz (no filter was applied). Intracellular solution contained 140 mM KCl, 2.5 mM MgCl 2 , 11 mM EGTA, 10 mM HEPES, 4 mM Mg-ATP, 5 mM sodium-phosphocreatine, and 0.2 mM Na-GTP, pH adjusted to 7.25 with KOH. Extracellular solution contained 150 mM NaCl, 5 mM KCl, 0.2 mM CaCl 2 , 3 M glycine, 10 mM D-glucose, and 10 mM HEPES, pH adjusted to 7.4 using NaOH. Whole-cell voltage-clamp currents were evoked by rapidly exchanging the extracellular solution to one containing NMDA for a period of 5 s every 60 s by means of a fast-step perfusion system (RSC 160; Bio-Logic Science Instruments, Claix, France). Data were analyzed using Pulse software (HEKA) for current measurements and Prism 5 (GraphPad Software Inc.) for statistics. In CRC experiments, data were fitted to the Hill equation, with fitted parameters values given Ϯ S.E. and where n refers to the range of repetitions for each data point. In all other cases, statistical data are expressed as means Ϯ S.E.M., where n represents the number of cells studied.
Single Concentration Binding in Rat Brain Cortical Membranes. Selected compounds were submitted for single concentration (10 M) displacement binding assay in rat cortical membranes to MDS Pharma Services (Taipei, Taiwan) Cerebral cortices from male Sprague-Dawley rats (200 -250 g, Charles River) were dissected immediately after animal decapitations. Cortices were weighed and homogenized in 15 volumes of ice-cold 5 mM Tris-HCl, pH 7.4 at 25°C. The homogenate was then centrifuged at 40,000g for 20 min at 4°C, and the pellet was washed five more times by resuspension and centrifugation as above. The pellet was then resuspended in 15 volumes of ice-cold 5 mM Tris-HCl containing 10 mM disodium EDTA and incubated for 20 min at 37°C. After three more resuspension and centrifugation steps in ice-cold 5 mM Tris-HCl, the final pellet was resuspended in three volumes of ice-cold 5 mM Tris-HCl buffer, and aliquots were frozen at Ϫ80°C until use. Protein concentration was determined by protein assay (Bio-Rad Laboratories, Milan, Italy) using bovine serum albumin as standard. Binding of [ 3 H]CGP 39653 (Sills et al., 1991) was performed in a plate containing 96 deep wells (Whatman, Clifton, NJ) in a final volume of 0.4 ml of 50 mM Tris-HCl, pH 7.4 at 25°C, and 1% DMSO. In displacement experiments, 10 nM [ 3 H]CGP 39653 (specific activity, 40.5 Ci/mmol; PerkinElmer Life and Analytical Sciences, Waltham, MA) was incubated for 30 min at 25°C with 24 g of protein in the absence or presence of competing compounds previously diluted in DMSO. Nonspecific binding was defined by 1 mM L-glutamate. In saturation experiments, increasing concentrations of [ 3 H]CGP 39653 (1.5-130 nM) were incubated as above. Reactions were stopped by filtration over GF/C filterplates (PerkinElmer Life and Analytical Sciences) followed by three washes with ice-cold 50 mM Tris-HCl, pH 7.4 at 25°C, using a Packard cell harvester (PerkinElmer Life and Analytical Sciences). Retained radioactivity was counted by a TopCount (PerkinElmer Life and Analytical Sciences) after the addition of 50 l/well of MicroScint 20 (PerkinElmer Life and Analytical Sciences).
Radioligand Binding Data Analysis. Radioligand binding data were analyzed with nonlinear regression by using Prism software. Determination of K D and B max of [ 3 H]CGP 39653 was assessed by elaborating saturation experiments using a one-site binding (hyperbola) equation, after checking, by use of F test, that this equation fit better compared with two-site binding equation. Competition curves for the known competitive antagonist NVP-AAM077 were statistically analyzed for a best one-or two-site competition fit. Competition curves for the other compounds for which the site of binding within the receptor was unknown were analyzed by using a four-parameter dose-response curve. Results are expressed as mean pIC 50 Ϯ S.E.M.
Results

FLIPR/Ca
2؉ Assay in U-2 OS Cells Expressing NMDAR. Reference NMDAR antagonists binding at different sites were profiled in NR1/NR2A and NR1/NR2B FLIPR assays, obtaining pIC 50 values in line with literature data (Table 1) . The preferential NR2A antagonist NVP-AAM077, binding at the glutamate site, showed pIC 50 values of 7.8 and 6.9 in NR1/NR2A and NR1/NR2B FLIPR assays, respectively (Table 1). Glycine antagonist GV196771A (Giacobbe et al., 1998; Quartaroli et al., 1999) inhibited NR2A-containing receptors with a slightly higher pIC 50 than NR2B-containing receptors (Table 1 ), in agreement with reported 10-fold lower affinity of the agonist glycine for NR2A-over NR2B-containing receptors (Priestley et al., 1995) . NR2B NTD ligands Ro 25-6981 (Fisher et al., 1997) and 606 (traxoprodil) showed detectable potency only in NR1/NR2B FLIPR assay (Table 1) . Pore blocker (ϩ)-MK-801 (dizocilpine maleate) had similar potency in both assays, whereas phencyclidine and memantine pore blockers showed slight preference for NR1/NR2B receptor combination (Table 1) The HTS CRC hits prioritization performed with LE and LLE indexes and selectivity profile resulted in the selection of compounds 1 to 3, 6, and 13 ( Fig. 1 and Table 2 ). These compounds were selective toward NR1/NR2A receptor with respect to NR1/NR2B subtype (Table 2) . Although showing molecular weight (377-480) and polar surface area (67-104, calculated according to Ertl et al., 2000) that are high for a central nervous system drug, they were further characterized. Subsequently, similarity searches were carried out to find more potent analogs possibly maintaining good selectivity. For this purpose, 127 analogs were selected by using similarity searches, then reduced to eight compounds (4, 5, 7-12) after discarding derivatives carrying undesirable reactive chemical functionalities such as oxyme or moieties unsuitable for a central nervous system drug such as carboxylate, as a result of visual compound inspection. Selected derivatives were tested in the FLIPR NR1/NR2A and NR1/ NR2B assays for pIC 50 determination. Results of this exploration have been reported together with original HTS hits in Table 2 .
Selected hits completely inhibited (92-100%) human recombinant NR1/NR2A receptor in FLIPR/Ca 2ϩ assay. Four hits (1-4) showed pIC 50 between 6.4 and 6.8; compounds 6 and 13 exhibited pIC 50 of 5.4 in NR1/NR2A assay. All hits resulted with pIC 50 Ͻ 4.3 in FLIPR NR1/NR2B assay ( Table 2) .
To clarify the inhibitory mechanism of action of five selected hits (1-3, 6, and 13) in FLIPR NR1/NR2A assay, 1 mM glycine, or 1 mM L-glutamate was added to U-2 OS expressing NR1/NR2A receptor 5 min after compound addition. Only 1 mM glycine, but not 1 mM L-glutamate, was able to surmount the effect of each of the five compounds ( Fig. 2 and Table 3 ). In the same test, NVP-AAM077 inhibitory effect was surmounted by 1 mM L-glutamate, but not by 1 mM glycine, whereas (ϩ)-MK-801 inhibitory effect was not surmounted by any of the two agonists (Table 3) .
FLIPR/Ca 2؉ Assay in Rat Cortical Cells. To confirm functional activity at native NMDAR, measurements of intracellular Ca 2ϩ were performed in rat cortical cultures. NMDA-evoked Ca 2ϩ response was completely blocked by pore blocker memantine with a pIC 50 value of 5.4 Ϯ 0.1 (n ϭ 5), suggesting that the NMDA-stimulated Ca 2ϩ influx is truly mediated by activation of NMDA receptors, whereas it was partially blocked (77 Ϯ 3%) with pIC 50 value of 7.3 Ϯ 0.1 (n ϭ 6) by NR1/NR2B receptor-selective antagonist Ro 25-6981, indicating that the majority of functional NMDAR contained NR2B subunit (Fig. 3A) , similarly to what was already described (Fisher et al., 1997 , Zhong et al., 1994 . Given the known partial antagonism of Ro 25-6981 (Fisher et al., 1997) , like that of any described selective NR2B antagonist at NTD site (Paoletti and Neyton, 2007) , the remaining NMDA-induced Ca 2ϩ response might be attributable to a mixed population of NMDAR, including both NR2A-and NR2B-containing receptors (Zhong et al., 1994) . The effect of compounds 1, 6, and 13 was studied in the presence of 1 M Ro 25-6981 to minimize the contribution of NR2B-containing receptors (at 1 M the antagonist is expected to give approximately 95% of its maximal effect). Compounds 1, 6, and 13 partially inhibited the NMDA-induced intracellular Ca 2ϩ response in a concentration-dependent manner (Fig. 3B) , with pIC 50 values of 6.4 Ϯ 0.4 (n ϭ 3), 5.4 Ϯ 0.2 (n ϭ 3), and 5.8 Ϯ 0.3 (n ϭ 3), respectively, and to a maximal level of 39 Ϯ 1, 46 Ϯ 6, and 66 Ϯ 8%, respectively. As shown in Fig. 4 , compound 1 inhibited the current induced by 30 M NMDA in the presence of 3 M glycine in a concentration-dependent manner, in HEK 293T transiently transfected with NR1/NR2A subunits. Fitting of data gave a pIC 50 value of 7.0 Ϯ 0.1 (n ϭ 3-9) corresponding to an IC 50 of 109 nM and a Hill slope of 1.4 Ϯ 0.3 (n ϭ 3-9). The compound at 3 M blocked 95.1 Ϯ 0.3% (n ϭ 3) of the NMDA current in NR1/NR2A-transfected cells.
Compound 1 was also tested in HEK 293T transiently transfected with NR1/NR2B or NR1/NR2D subunits: it was inactive below a concentration of 30 M on the current induced by 30 M NMDA in the presence of 3 M glycine in either NR1/NR2B-or NR1/NR2D-transfected cells.
Binding Studies in Rat Cortical Membranes. To gain insight into their site of action, three compounds (1, 6, and 13) were selected for single concentration (10 M (Sills at al., 1991) , glycine site, pore, and NR2B NTD of NMDAR, respectively.
Highest inhibition values were obtained with compounds 1 Table 3 . (Table 4) . Therefore, more detailed [ 3 H]CGP 39653 radioligand binding assays were performed. In saturation experiments, [ 3 H]CGP 39653 displayed single-site, saturable binding to rat cerebral cortex membranes. The negative logarithm of the apparent dissociation constant (pK d ) was 7.5 Ϯ 0.03 and the calculated maximum binding capacity (B max ) was 5745 Ϯ 373 fmol/mg protein (n ϭ 3). In competition experiments, the known competitive NR1/NR2A preferring antagonist NVP-AAM077 showed a biphasic displacement curve with pIC 50 values of 8.5 Ϯ 0.2 and 7.3 Ϯ 0.2. The percentage of higher affinity binding sites, most likely corresponding to NR1/NR2A receptors, was 54 Ϯ 9%. Compounds 1 and 6 partially inhibited (Table 5 and Fig. 5 ).
Selectivity Profile of Selected Hits. Compounds 1, 6, and 13 showed selectivity in a panel of more than 30 targets, including ion channels and seven-transmembrane receptors. The high degree of specificity of compounds 1, 6, and 13 was also demonstrated in several additional assays. In a variety of binding and functional tests, they did not interact with ion channels (transient receptor potential vanilloid 4, human Values are pIC 50 mean Ϯ S.D. from NR1/NR2A FLIPR/Ca 2ϩ assay in the presence of 1 mM glycine (Gly) or 1 mM L-glutamate (Glu), added 5 min after compound addition. The number of independent experiments is indicated in parentheses. Maximal inhibition was 92 to 100% for all listed compounds. The ability of 1 mM glycine to surmount inhibitory effect of compounds 1-3, 6, and 13 is reflected in pIC 50 values Ͻ4.3, measured 5 min after glycine addition. Glycine (1 mM) is not able to surmount NVP-AAM077 inhibitory effect. (ϩ)-MK-801 inhibitory effect was not surmounted by either of the two agonists.
Compound pIC 50
ϩ 1 mM Gly ϩ 1 mM Glu ether-à -go-go-related gene channel, hNaV1.5 sodium channel), receptors of nonpeptide (adenosine, adrenergic, cannabinoid, dopamine, histamine, acetylcholine, serotonin) or peptide ligands (neurokinin, opioid, vasopressin) , enzymes (cyclooxygenase, phosphodiesterase), or transporter (norepinephrine, serotonin) when tested at 10 M concentration.
Discussion
Novel antagonists for human recombinant NR1/NR2A receptor were discovered through a FLIPR/Ca 2ϩ HTS approach (Table 2) , and the potency for selected compounds was confirmed in electrophysiology patch-clamp experiments and rat brain cortical cells FLIPR/Ca 2ϩ assay (Figs. 3B and 4); in addition, displacement of radioligands at different NMDAR sites was verified in rat brain cortical membranes (Fig. 5 and Tables 4 and 5 ).
All selected hits were able to fully block (92-100%, Table 2 ) human recombinant NR1/NR2A receptor, the more potent compound 1 displaying submicromolar potency and higher than 300-fold selectivity compared with NR1/NR2B receptor in both FLIPR/Ca 2ϩ and electrophysiology patch-clamp experiments (Table 2 and Fig. 4) . Patch-clamp experiments also showed that compound 1 is inactive at NR1/NR2D receptors at 30 M concentration, whereas the effect on receptors containing NR2C subunit has not yet been tested.
Replacing the phenyl group of sulfonamide derivative 1 with different R 5 groups (compounds 2-4) did not result in activity increase at NR2A FLIPR/Ca 2ϩ assay (Table 2) . Loss of activity was observed with the bis-methylated analog 5. In the shorter subseries (compounds 6-11) a drop of activity of at least 10-fold was observed, the 3-pyridinyl derivative 6 and tetrahydro-2-furanyl derivative 7 being the most active. In particular, when R 5 is a pyridinyl residue (compounds 6, 8, and 10), the 3-substitution was the preferred one. Further modification (compound 12) was detrimental for activity. This is the first evidence describing compounds with such a high degree of selectivity for NR1/NR2A compared with NR1/NR2B receptor, to the best of our knowledge. NR1/ NR2A-selective molecules were described in the literature, including the competitive NMDAR antagonists perzinfotel (EAA-090) or NVP-AAM077. Perzinfotel was shown to be 10 times more potent at blocking NR2A-versus NR2B-or NR2C-containing NMDARs (Sun et al., 2004) . NVP-AAM077 was originally described to displace [ 3 H]CGP 39653 with nanomolar affinity, displaying greater than 100-fold preferential blockade for NR2A-compared with NR2B-containing receptors in functional assays (Auberson et al., 2002) . More detailed studies have shown that NVP-AAM077 displays only approximately 10-fold preference for NR2A-over NR2B-containing receptors (Neyton and Paoletti, 2006) , and the latter is the degree of selectivity observed for NVP-AAM077 in our FLIPR/Ca 2ϩ experimental conditions (Table 1 ). To confirm affinity and functional activity at native NMDARs, studies were performed using membranes and cell cultures, respectively, from rat brain cortex. Rat brain cortex and derived cells in culture are known to express both NR2A and NR2B subunits (Zhong et al., 1994; Takai et al., 2003 (Laurie and Seeburg, 1994; Kendrick et al., 1996) , given their NR1/NR2A-selective profile at recombinant NMDAR and the inability of glutamate to surmount their inhibitory effect at recombinant NR1/NR2A (Table 3) .
Glycine site antagonist 5,7-dichlorokynurenate produced partial inhibition of [ 3 H]CGP 39653 binding (Reynolds, 1994) , and GV150526A competitively reversed the high-affinity component of [ 3 H]CGP 39653 binding inhibition by glycine (Mugnaini et al., 2001) . It is noteworthy that our FLIPR/Ca 2ϩ mode of action experiments showed that glycine could surmount the inhibitory effect of compounds 1 to 3, 6, and 13 but not of NVP-AAM077, which was surmounted by 1 mM L-glutamate instead (Table 3 ). For the above reasons, hits 1 to 3, 6, and 13 might be glycine site antagonists; however, the tested compounds 1, 6, and 13 at 10 M induced only 24, 13, and 14% displacement in rat native receptors, respectively, of glycine site antagonist [ 3 H]MDL 105,519 binding (Table 4) . Although [ 3 H]MDL 105,519 displacement binding assay remains to be performed with recombinant human NR1/NR2A receptor, data obtained in rat brain cortical membranes suggest that compounds 1, 6, and 13 are acting not at the glycine site but at a site allosterically modulated by glycine. In addition, no glycine site antagonist has been reported in literature showing a complete selectivity for NR1/NR2A receptor over NR1/NR2B. Indeed, glycine site antagonists generally display only slight preference for NR2A-containing receptors, as it is observed for GV196771A in our FLIPR/Ca 2ϩ assay (Table1), because of the approximately 10-fold lower affinity for glycine of receptors containing the NR2A subunit than other NR2 subunits (Dingledine et al., 1999) .
It is therefore tempting to speculate that the discovered hits bind to a region of NR1/NR2A receptor that is near both glutamate and glycine binding sites. Novel hits were surmounted by glycine but not by L-glutamate in functional assay ( Fig. 2 and (Tables 4 and 5 ). Therefore, these compounds might preferentially interact with or at the interface between both agonist binding domains (ABDs) of NR1/NR2A receptor, central to agonist/ competitive antagonist binding and to activation gating. Glycine and glutamate binding sites are located within NR1 and NR2 subunit ABDs, respectively, and not between subunits (Mayer, 2006) . Agonist binding results in closure of the "clamshell"-like ABD, whereas antagonist binding stabilizes the binding domain clamshell in an open conformation, and mechanisms for allosteric coupling between glycine and glutamate ABDs have been proposed (Mayer, 2006) . In addition, the existence of independent NR1 and NR2 subunit activating transitions has been postulated according to single-channel recordings (Erreger et al., 2005) , and novel hits might preferentially interact with NR1/NR2A having glycine and glutamate clam shell ABDs open and closed, respectively (Fig. 6 ).
It will be necessary to perform X-ray crystal studies on purified recombinant receptor, or part of it, to clarify the site of action of discovered hits (such as compound 1, 6, or 13) and gain insight on structural determinants of its NR1/NR2A selectivity. Binding studies on both recombinant receptors and isolated soluble ligand-binding domains, site-directed mutagenesis, and chimeric receptor studies might also be useful in clarifying the novel hits interactions with NR2A and/or NR1 domains. Compound 1 and other described hits may constitute useful tools or chemical starting points to investigate the role of NR1/NR2A receptor in physiological and pathological conditions. 
